key: cord-1022609-f1hh63qc
authors: Adapa, Arjun Rohit; Jumaa, Mouhammad A.; Siddiqui, Fazeel M.; Dawod, Giana; Zaidat, Osama O.; Gurm, Hitinder S.; Pandey, Aditya S.
title: Trends in interventional stroke device utilization during the COVID-19 pandemic
date: 2021-09-02
journal: Clin Neurol Neurosurg
DOI: 10.1016/j.clineuro.2021.106931
sha: 22178106a171c818beb7dc32297c540d67d5122c
doc_id: 1022609
cord_uid: f1hh63qc

OBJECTIVES: The collateral effect of the COVID-19 pandemic on interventional stroke care is not well described. We studied this effect by utilizing stroke device sales data as markers of interventional stroke case volume in the United States. METHODS: Using a real-time healthcare device sales registry, this observational study examined trends in the sales of thrombectomy devices and cerebral aneurysm coiling from the same 945 reporting hospitals in the U.S. between January 22 and June 31, 2020, and for the same months in 2018 and 2019 to allow for comparison. We simultaneously reviewed daily reports of new COVID-19 cases. The strength of association between the cumulative incidence of COVID-19 and procedural device sales was measured using Spearman rank correlation coefficient (CC). RESULTS: Device sales decreased for thrombectomy (-3.7%) and cerebral aneurysm coiling (-8.5%) when comparing 2019 to 2020. In 2020, thrombectomy device sales were negatively associated with the cumulative incidence of COVID-19 (CC -0.56, p < 0.0001), with stronger negative correlation during April (CC -0.97, p < 0.0001). The same negative correlation was observed with aneurysm treatment devices (CC -0.60, p < 0.001), with stronger correlation in April (CC -0.97, p < 0.0001). CONCLUSIONS: The decline in sales of stroke interventional equipment underscores a decline in associated case volumes. Future pandemic responses should consider strategies to mitigate such negative collateral effects.

Studies have revealed a negative collateral effect of the COVID-19 pandemic on emergent stroke and cardiovascular care in the U.S. as well as globally [1] [2] [3] [4] . As the COVID-19 pandemic continues, there is a call to understand the magnitude of such collateral effects in the U.S. and thus better guide future responses in minimizing such effects [2, 4] . While the collateral effect of the COVID-19 pandemic on stroke has been reported at the regional level in the U.S., we aimed to study this effect in real time at the national level by utilizing interventional stroke device sales data as a marker of interventional stroke case volumes.

Using a device sales data registry from the Decision Resources Group, a healthcare research and consulting company, we examined trends in the sales of cerebrovascular thrombectomy and cerebral aneurysm devices from the same 945 reporting hospitals in the U.S. between January 22, 2020 (date of first coronavirus case in the U.S.) and June 31, 2020. This device sales data registry contains all purchase order transactions from each reporting hospital's purchase order system. As such, data are collected directly from each hospital's purchase order record. The full list of devices included in the analysis are found in the Online Supplement.

Trends in device sales in 2020 were compared with trends during the same periods in 2019 and 2018. Geographic regions were defined in accordance with the U.S. Census Bureau-South, Midwest, West, and Northeast. We simultaneously reviewed daily reports of new COVID-19 cases based on positive results of SARS-CoV-2 nasopharyngeal swab testing (Centers for J o u r n a l P r e -p r o o f Disease Control), and the incidence of COVID-19 was represented as the number of COVID-19 cases per 100,000 persons.

Device sales per month were extrapolated as a continuous variable by dividing the difference in device sales tallied at the end of each month by the number of days in that month.

We computed the Spearman rank correlation coefficient (R) to measure the strength of the correlation between the cumulative incidence of COVID-19 and procedural device sales in the U.S. and for each geographic region. The proportion (%) of device sales for each device type per month was calculated by dividing the number of devices sold in a month by the total sales of that device during the study period. The COVID-19 case rate and proportion of device sales were plotted together by region. Analyses were performed using RStudio version 1.1.456 (https://rstudio.com).

The percent changes in device sales from 2019 to 2020 for thrombectomy and cerebral aneurysm devices were -3.7% and -8.5%, respectively. The percent changes in device sales from 2018 to 2019 for thrombectomy and cerebral aneurysm devices, meanwhile, were +30.0% and +3.7%, respectively. In April 2020, there was a sharp decline in device sales: -5% for thrombectomy device sales and -5.8% for aneurysm device sales. This decline in sales reversed course with increased sales during May 2020 for aneurysm devices and during June 2020 for all devices.

During the study period in 2020, a total of 2,934,455 cases of COVID-19 were reported in the U.S. During the same period, there were a total of 11,132 thrombectomy device sales and 27,479 aneurysm device sales (Table 1) . During the corresponding period in 2019, there were 11,562 thrombectomy device sales and 30,027 aneurysm device sales. As such, the percent changes in device sales from 2019 to 2020 for thrombectomy and aneurysm devices were -3.7% and -8.5%, respectively. These data are especially notable in contrast to the increase in thrombectomy and aneurysm device sales from 2018 to 2019. When looking at device sales by region, the Midwest had the greatest magnitude of decline in thrombectomy device sales, with a percent change of -12.2% from 2019 to 2020. Notably, the West had the greatest decline in aneurysm device sales, with a percent change of -11.3% from 2019 to 2020.

The proportion of thrombectomy device sales by month in 2020 was strongly and negatively associated with the cumulative incidence of COVID-19 in the U.S. overall (Spearman rank correlation coefficient (CC), -0.56, p < 0.0001), with even stronger correlation during April 2020 (CC -0.97, p < 0.0001) (Fig 1) . Examining these trends by region revealed a significantly negative association between thrombectomy device sales and the incidence of COVID-19 in the South (CC -0.59, p < 0.001), Midwest (CC -0.19, p = 0.04), West (CC -0.66, p < 0.0001), and Northeast (CC -0.75, p < 0.0001), with the strongest association being in the Northeast. For all regions, the greatest decline in the rate of thrombectomy device sales in 2020 was seen in April.

There was a strongly negative association between aneurysm device sales in 2020 and COVID-19 incidence in the U.S. overall (CC -0.60, p < 0.001), with even stronger correlation in April (CC -0.97, p < 0.0001) (Fig 2) . This was also seen in each region individually. Examining J o u r n a l P r e -p r o o f these trends by region revealed a significantly negative association between aneurysm device sales and the incidence of COVID-19 in the South (CC -0.54, p < 0.001), Midwest (CC -0.68, p < 0.0001), West (CC -0.65, p < 0.0001), and Northeast (CC -0.48, p < 0.0001).

To understand the overall impact of the COVID-19 pandemic on interventional stroke care, we have studied the sales of devices utilized for thrombectomy and cerebral aneurysm treatment procedures from 2018 to 2020, thus extrapolating the changes in device sales to procedural volume changes. Based on sales data from 945 hospitals in the United States, we report a significant decline in device sales from 2019 to 2020 (January through June) relating to thrombectomy (-3.7%) and cerebral aneurysm treatment (-8.5%), which is in contrast to an increase in device sales from 2018 to 2019. The proportion of thrombectomy device sales by month in 2020 was strongly and negatively associated with the cumulative incidence of COVID-19 in the U.S. overall. Even in April 2020, there was a 5% decline in thrombectomy device sales relative to March, and the South was the most impacted region with a decline of 6.8%. While stroke centers in Michigan and northwest Ohio reported a 75.6% reduction in the rate of mechanical thrombectomy procedures for March 2020 compared to February 2020 [4] , and national imaging during stroke care was reported to have decreased by 39% [3] , we are reporting a much lower decline in thrombectomy equipment sales throughout the U.S. Thus, while the collateral effect on emergent thrombectomy stroke care appears to be real, the degree of impact may be less than previously reported in smaller regional series. Thrombectomy is a unique procedure as the devices utilized, specifically stent retrievers and suction thrombectomy catheters, are highly specific to this emergent procedure. Therefore, studying thrombectomy J o u r n a l P r e -p r o o f device sales provides a unique methodology for evaluating the COVID-19 impact on emergent delivery of interventional stroke care. With a decline in the rate of COVID-19 cases, we saw a rise of thrombectomy device sales, and thus, cases, in the month of June.

Other studies have reported trends of decreasing stroke admissions during the COVID-19

pandemic, but reports have primarily focused on regional patterns. For example, a study conducted at a tertiary care hospital in West Michigan demonstrated a reduction of cases of acute ischemic stroke during the stay-at-home order from March 24 to April 23, 2020, but this finding was not statistically significant [5] . A similar study found a reduction in stroke admissions of up to 39.5% in May 2020 compared to the pre-COVID-19 era, defined as December 1, 2019 to defined differently in each of the studies. By utilizing device sales as a marker of procedural case volume, our study is the first to report both national and regional trends in interventional stroke care during the COVID-19 pandemic in the U.S.

When evaluating the aneurysm coiling sales data, one must account for these devices being utilized for elective as well as emergent procedures. Thus, the impact of the pandemic on the volume of aneurysm treatment procedures will be greater given a combination of the collateral effect as well as the decline related to the cessation of elective surgical procedures post COVID-19 pandemic. This is in alignment with the drop of aneurysm equipment sales by 8.5%

when comparing 2020 to 2019. Device sales for aneurysm treatment were negatively correlated with the incidence of COVID-19, thereby underscoring an association of the pandemic to a decline in aneurysm interventions. The collateral effect of the COVID-19 pandemic on cerebrovascular interventions appears to be a real effect with a decline in sales of associated equipment during April followed by increases in June 2020.

We report a negative correlation between the rising incidence of COVID-19 infections and the sales of stroke procedural equipment during the study period of January to June 2020 within the United States. This negative collateral effect appeared to be stabilizing with the rise in 

The impact of the COVID-19 pandemic on emergency department visits and patient safety in the United States

Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic

Collateral effect of Covid-19 on stroke evaluation in the United States

Letter: COVID-19 pandemic-The bystander effect on stroke care in Michigan

Impact of a stay-at-home order on stroke admission, subtype, and metrics during the COVID-19 pandemic

The impact of COVID-19 on acute ischemic stroke admissions: Analysis from a community-based tertiary care center

Stroke care within the COVID-19 pandemic-increasing awareness of transient and mild stroke symptoms needed

Code stroke patient referral by emergency medical services during the public COVID-19 pandemic lockdown

Impact of COVID-19 on stroke caseload in a major hyperacute stroke unit

Management of acute ischemic stroke in the interventional neuroradiology suite during the COVID-19 pandemic: A global survey

Writing -Original draft, Writing -Review and editing. Mouhammad Jumaa: Conceptualization, Writing -Review and editing. Fazeel Siddiqui: Conceptualization, Writing -Review and editing, Supervision. Giana Dawod: Writing -Review and editing. Osama Zaidat: Writing -Review and editing. Hitinder Gurm: Writing -Review and editing. Aditya S. Pandey: Conceptualization, Methodology, Formal analysis, Writing -Original draft